Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPickering, Lisa M.-
dc.contributor.authorTovey, Holly-
dc.contributor.authorElliott, Tony-
dc.contributor.authorBurnett, Stephanie M.-
dc.contributor.authorBahl, Amit-
dc.contributor.authorKirkbride, Peter-
dc.contributor.authorMitra, Anita-
dc.contributor.authorThomson, Alastair H.-
dc.contributor.authorVasudev, Naveen-
dc.contributor.authorSlade, Rachel-
dc.contributor.authorTregellas, Lucy-
dc.contributor.authorMorgan, Bruno-
dc.contributor.authorHassall, Alison-
dc.contributor.authorHall, Emma-
dc.contributor.authorNicholson, Steve-
dc.identifier.citationJournal of Clinical Oncology, 2018, 36 (6) suppl. pp. 547-547en
dc.descriptionAbstract onlyen
dc.description.abstractBackground: Platinum-based combination chemotherapy regimens are used in the treatment of carcinoma of the penis, but toxicity limits their value for patients with metastatic disease. This trial aims to define both the toxicity and the rate of disease control for the non-platinum cytotoxic agent Vinflunine. Methods: A phase II single-arm trial was designed to demonstrate a clinical benefit rate of at least 40% and to exclude a rate of less than 15% (p0 = 0.15, p1 = 0.40, α = 0.05, β = 0.80, Fleming-A’hern exact design). 22 evaluable patients were required. Key eligibility criteria included measurable, histologically-proven squamous cell carcinoma of the penis staged as M1; or M0, Tx, N3; or M0, Tx, N2 and deemed inoperable by multidisciplinary team; or M0, T4 any N. Patients were required to have ECOG performance status of 0, 1 or 2 and adequate hepatic and renal function. Treatment comprised four 21-day cycles of vinflunine (320mg/m2) with RECIST v1.1 restaging following cycle 4 (response primary endpoint). Patients deemed to be benefitting from treatment were permitted to continue vinflunine at the discretion of the treating clinician until progression or unacceptable toxicity. Results: 25 patients were recruited from 8 UK centres between June 2014 and May 2017. Median age was 68 years; 19 patients had metastatic (M1) disease. All patients have completed trial treatment and primary endpoint assessment. Data cleaning for the primary analysis is currently in progress, with the snapshot for the primary analysis due in October 2017 and primary analysis to be presented to the trial oversight committees in November 2017. Conclusions: It is hoped that single-agent vinflunine will be associated with a favourable toxicity profile combined with meaningful clinical responses. The results will be available for presentation at the meeting. Clinical trial information: NCT02057913.en
dc.publisherAmerican Society of Clinical Oncologyen
dc.rightsCopyright © 2018, American Society of Clinical Oncology. Deposited with reference to the publisher’s open access archiving policy. (
dc.subjectScience & Technologyen
dc.subjectLife Sciences & Biomedicineen
dc.titleVinCaP: A phase II trial of vinflunine chemotherapy in locally-advanced and metastatic carcinoma of the penis (CRUK/12/021).en
dc.typeConference Paperen
dc.description.presentedGenitourinary Cancers Symposium, San Francisco, CAen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCESen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicineen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/School of Medicine/Cancer Research Centreen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themesen
pubs.organisational-group/Organisation/COLLEGE OF LIFE SCIENCES/Themes/Canceren
Appears in Collections:Conference Papers & Presentations, Dept. of Cancer Studies and Molecular Medicine

Files in This Item:
There are no files associated with this item.

Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.